Hier finden Sie grundlegende Angaben zu klinischen Studien des Comprehensice Cancer Centers Mainfranken (CCC MF)
Filter aktiv
Seite 1 - Studien 1 bis 10 von insgesamt 11
- Rekrutierung läuftMulticenter, Open-label, Phase 1 Study of Allo-RevCAR01-T-CD123 Consisting of Genetically Modified T cells Carrying Reverse Chimeric Antigen Receptors (Allo-RevCAR01-T) in Combination With CD123 Target Module (R-TM123) for the Treatment of Patients With Selected Hematologic Malignancies Positive for CD123IndikationenMolekulare Marker
- Rekrutierung läuftA Prospective Phase I/II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Tafasitamab (MOR00208) in Pediatric Patients with Relapsed or Refractory Acute B Lineage Leukemia. Ant-CD19-ALL.Molekulare Marker
- Rekrutierung läuftWirksamkeit und Sicherheit von Carfilzomib in Kombination mit Ibrutinib oder Ibrutinib alleine bei Patienten mit Morbus Waldenström (CZAR-1)
- Rekrutierung läuftA Phase 1/2 Study to Evaluate the Safety and Efficacy of AZD0486 in Adolescent and Adult Participants with Relapsed or Refractory B-Cell Acute Lymphoblastic LeukaemiaMolekulare Marker
- Rekrutierung läuftA Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5492, a T cell-engaging Antibody Targeting CD20 in Subjects with Relapsed or Refractory B-Cell Malignancies (TITANium)Molekulare Marker
- Rekrutierung läuftA RANDOMIZED, OPEN-LABEL, MULTICENTER, GLOBAL, PHASE 2 TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF EPCORITAMAB (GEN3013; DUOBODY®-CD3×CD20) AS MONOTHERAPY OR IN COMBINATION WITH LENALIDOMIDE AS FIRST-LINE THERAPY FOR ANTHRACYCLINE-INELIGIBLE SUBJECTS WITH DIFFUSE LARGE B-CELL LYMPHOMAMolekulare Marker
- Rekrutierung läuftEine offene, forschungsinitiierte Phase I/II – Studie mit Venetoclax in Kombination mit Blinatumomab Immuntherapie bei erwachsenen Patienten mit rezidivierter/refraktärer ALLMolekulare Marker
- Rekrutierung läuftLong-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified CellsMolekulare Marker
- Rekrutierung läuftA Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP Compared to R-CHOP in Subjects with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)Molekulare Marker
- Rekrutierung läuftNon-Hodgkin Lymphoma: Epcoritamab in Combination with Anti-Neoplastic AgentsMolekulare Marker